PDCD1 and neoplasm: Another report suggests that the unidentified immune activity in the tumor may enhanced the effect of nivolumab in the early phase, which results in T cell recognition and activity against antigens in healthy tissues provide improving treatment with ICIs and important clues on the mechanism of PD-1-mediated toxicity and antitumor efficacy35.